The utility of monoclonal antibodies in the imaging of prostate cancer

Seminars in Urologic Oncology

Volumn 20, Issue 3, 2002, Pages 211-218

  Yao, Daniel ^a,b,c   Trabulsi, Edouard J ^a,b,c   Kostakoglu, Lale ^a,b,c   Vallabhajosula, Shankar ^a,b,c   Joyce, Maureen A ^a,b,c   Nanus, David M ^a,b,c   Milowsky, Matthew ^a,b,c   Liu, He ^a,b,c   Goldsmith, Stanley J ^a,b,c  

^a Department of Medicine ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Imaging; Immunoconjugates; Monoclonal antibodies; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANTIBODY CONJUGATE; CAPROMAB PENDETIDE IN 111; INDIUM 111; LUTETIUM; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; YTTRIUM 90;

ANTIGEN EXPRESSION; BINDING SITE; BONE; CANCER RESISTANCE; CANCER STAGING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EQUIPMENT; HUMAN; IMMUNOSCINTIGRAPHY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOFT TISSUE; TARGET ORGAN;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; MALE; PROSTATIC NEOPLASMS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036672504     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.36250     Document Type: Review

References (48)

1. Cancer statistics, 2002
2. The influence of hormonal therapy on survival of men with advanced prostatic cancer
3. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria
4. Continuous cultures of fused cells secreting antibody of predefined specificity
5. Current status of monoclonal antibodies for imaging and therapy of prostate cancer
6. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
7. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line
8. Prostate-specific membrane antigen: Evidence for the existence of a second related human gene
9. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
10. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11
11. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene
12. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells
13. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase
14. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase)
15. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
16. Enzyme Nomenclature. Recommendations 1992. Corrections and additions (1997)
17. Expression of the prostate-specific membrane antigen
18. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
19. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases
20. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids
21. Prostate-specific membrane antigen expression in normal and malignant human tissues
22. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
23. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostatespecific membrane antigen
24. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
25. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer
26. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: Results of a multi-institutional cooperative trial
27. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy
28. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy
29. Immunoscintigraphy of prostatic cancer: Preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)
30. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy
31. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy: The ProstaScint Study Group
32. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: Positron emission tomography and biopsy correlation
33. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
34. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
35. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
36. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen
37. Location of prostatespecific membrane antigen in the LNCaP prostate carcinoma cell line
38. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
39. Constitutive and antibody-induced internalization of prostate-specific membrane antigen
40. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
41. Target antigens for prostate cancer immunotherapy
42. ProstaScint scan for staging prostate cancer
43. Monoclonal antibody therapy
44. Radioimmunoscintigraphy of pelvic lymph nodes with 111 indium-labeled monoclonal antibody CYT-356
45. Monoclonal antibody imaging of recurrent and metastatic prostate cancer
46. Imaging prostate cancer with technetium-99m-7E11.C5.3 (CYT-351)
47. Radioimmunoscintigraphy with 111 indium-labeled CYT- 356 for the detection of occult prostate cancer recurrence
48. Indium-111 capromab monoclonal antibody: Utility in differentiating local versus distant relapse after radical prostatectomy